Posts

Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis
Business, Editorial, NewsOur resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.

Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors
Business, EditorialPsychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.

Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
Business, NewsOur resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial sense.

My Favorite Psychedelic Stocks: Part 1
Business, EditorialOur resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.

Psychedelic Business Spotlight – February 18
Business, Stock ReportsThis week in psychedelic business news: Nova Mentis makes progress on autism; atai donates to MAPS; Cathie Wood eyes more psychedelic stocks.

Cathie Wood’s ARK Genomic Revolution ETF Buys Psychedelic Stock
Business, EditorialOur resident Psychedelic Investor explains why this is an important moment for the psychedelics sector.

4 Tips for Investing in Psychedelic Stocks During a Market Downturn
Business, InvestingFriendly advice for responsibly managing speculative bets on psychedelic stocks that may rise like a phoenix or burn to the ground.

Psychedelic Business Spotlight — January 28
Business, Stock ReportsThis week in psychedelic business news: A major player begins manufacturing; another rebrands; and one of the biggest gets bigger.

Psychedelic Business Spotlight – December 17
Business, Stock ReportsThis week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Psychedelic Business Spotlight: October 15
Business, Stock ReportsThis week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.